본문으로 건너뛰기
← 뒤로

Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.

1/5 보강
Journal of hepato-biliary-pancreatic sciences 📖 저널 OA 40.9% 2024: 3/9 OA 2025: 9/17 OA 2026: 6/18 OA 2024~2026 2026
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
185 patients were included (non-elderly: 148, elderly: 37).
I · Intervention 중재 / 시술
NAC GS
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
While initiation of AC was delayed and RDI of adjuvant S-1 was lower in elderly patients, RFS and OS did not significantly differ between groups. [CONCLUSIONS] NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.

Takeda T, Ozaka M, Sasaki T, Inoue Y, Hirai T, Mie T

📝 환자 설명용 한 줄

[BACKGROUND] Neoadjuvant chemotherapy (NAC) with gemcitabine and S-1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p < 0.001

이 논문을 인용하기

↓ .bib ↓ .ris
APA Takeda T, Ozaka M, et al. (2026). Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.. Journal of hepato-biliary-pancreatic sciences. https://doi.org/10.1002/jhbp.70058
MLA Takeda T, et al.. "Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.." Journal of hepato-biliary-pancreatic sciences, 2026.
PMID 41614562 ↗
DOI 10.1002/jhbp.70058

Abstract

[BACKGROUND] Neoadjuvant chemotherapy (NAC) with gemcitabine and S-1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear.

[METHODS] We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non-elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence-free survival (RFS), and overall survival (OS).

[RESULTS] A total of 185 patients were included (non-elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S-1 was lower in elderly patients, RFS and OS did not significantly differ between groups.

[CONCLUSIONS] NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반